PAP
NKTR icon

Persistent Asset Partners’s Nektar Therapeutics NKTR Stock Holding History

Persistent Asset Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,560
Closed -$8.67K – 277
2025
Q2 		$8.67K Buy
1,560
+1,456
+1,400% +$16.3K 0.01% 171
2025
Q1 		$36.7K Hold
104
– – 0.03% 138
2024
Q4 		$73.4K Buy
+104
New +$1.83K 0.06% 108

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Persistent Asset Partners's NKTR Position: Q1 2026 in Review

Persistent Asset Partners opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 5,820 shares worth $419K. The stake represents 0.16% of the portfolio and ranks #124 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in NKTR as recently as Q3 2025.

Persistent Asset Partners first reported a position in NKTR in Q4 2024 and has held it in 3 quarters since. The position peaked at $983K in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Persistent Asset Partners held 5,820 shares of Nektar Therapeutics worth $419K as of Q1 2026.
  • Nektar Therapeutics was a new Persistent Asset Partners position in Q1 2026.
  • Nektar Therapeutics made up 0.16% of Persistent Asset Partners's portfolio in Q1 2026, its #124 holding.
  • Persistent Asset Partners first reported a position in Nektar Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Persistent Asset Partners's Nektar Therapeutics position peaked at $983K in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.